These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 22464548)

  • 1. HDAC6 as a target for antileukemic drugs in acute myeloid leukemia.
    Hackanson B; Rimmele L; Benkißer M; Abdelkarim M; Fliegauf M; Jung M; Lübbert M
    Leuk Res; 2012 Aug; 36(8):1055-62. PubMed ID: 22464548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of 1,2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation.
    Ashwini N; Garg M; Mohan CD; Fuchs JE; Rangappa S; Anusha S; Swaroop TR; Rakesh KS; Kanojia D; Madan V; Bender A; Koeffler HP; Basappa ; Rangappa KS
    Bioorg Med Chem; 2015 Sep; 23(18):6157-65. PubMed ID: 26299825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines.
    Savickiene J; Borutinskaite VV; Treigyte G; Magnusson KE; Navakauskiene R
    Eur J Pharmacol; 2006 Nov; 549(1-3):9-18. PubMed ID: 16978604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.
    Bradbury CA; Khanim FL; Hayden R; Bunce CM; White DA; Drayson MT; Craddock C; Turner BM
    Leukemia; 2005 Oct; 19(10):1751-9. PubMed ID: 16121216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells.
    Barbetti V; Gozzini A; Rovida E; Morandi A; Spinelli E; Fossati G; Mascagni P; Lübbert M; Dello Sbarba P; Santini V
    Oncogene; 2008 Mar; 27(12):1767-78. PubMed ID: 17891169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
    Liu ZH; Li J; Xia J; Jiang R; Zuo GW; Li XP; Chen Y; Xiong W; Chen DL
    Chem Biol Interact; 2015 Dec; 242():227-34. PubMed ID: 26482938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
    Sutheesophon K; Nishimura N; Kobayashi Y; Furukawa Y; Kawano M; Itoh K; Kano Y; Ishii H; Furukawa Y
    J Cell Physiol; 2005 May; 203(2):387-97. PubMed ID: 15515013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts.
    Gozzini A; Rovida E; Dello Sbarba P; Galimberti S; Santini V
    Cancer Res; 2003 Dec; 63(24):8955-61. PubMed ID: 14695213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
    Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
    ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor, trichostatin A.
    Ninios YP; Sekeri-Pataryas KE; Sourlingas TG
    Leuk Res; 2010 Jun; 34(6):786-92. PubMed ID: 19782399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cu2+ is required for pyrrolidine dithiocarbamate to inhibit histone acetylation and induce human leukemia cell apoptosis.
    Chen J; Du C; Kang J; Wang J
    Chem Biol Interact; 2008 Jan; 171(1):26-36. PubMed ID: 17961528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy.
    Ontoria JM; Altamura S; Di Marco A; Ferrigno F; Laufer R; Muraglia E; Palumbi MC; Rowley M; Scarpelli R; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
    J Med Chem; 2009 Nov; 52(21):6782-9. PubMed ID: 19888759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.
    Golay J; Cuppini L; Leoni F; Micò C; Barbui V; Domenghini M; Lombardi L; Neri A; Barbui AM; Salvi A; Pozzi P; Porro G; Pagani P; Fossati G; Mascagni P; Introna M; Rambaldi A
    Leukemia; 2007 Sep; 21(9):1892-900. PubMed ID: 17637810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deficient histone acetylation in acute leukemia and the correction by an isothiocyanate.
    Xiao L; Huang Y; Zhen R; Chiao JW; Liu D; Ma X
    Acta Haematol; 2010; 123(2):71-6. PubMed ID: 20051681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting aberrant transcriptional repression in acute myeloid leukemia.
    Moe-Behrens GH; Pandolfi PP
    Rev Clin Exp Hematol; 2003 Jun; 7(2):139-59. PubMed ID: 14763160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential protein acetylation induced by novel histone deacetylase inhibitors.
    Glaser KB; Li J; Pease LJ; Staver MJ; Marcotte PA; Guo J; Frey RR; Garland RB; Heyman HR; Wada CK; Vasudevan A; Michaelides MR; Davidsen SK; Curtin ML
    Biochem Biophys Res Commun; 2004 Dec; 325(3):683-90. PubMed ID: 15541343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
    Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
    Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases.
    Li G; Jiang H; Chang M; Xie H; Hu L
    J Neurol Sci; 2011 May; 304(1-2):1-8. PubMed ID: 21377170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
    Ferrara FF; Fazi F; Bianchini A; Padula F; Gelmetti V; Minucci S; Mancini M; Pelicci PG; Lo Coco F; Nervi C
    Cancer Res; 2001 Jan; 61(1):2-7. PubMed ID: 11196162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.